Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | DRD4 | P21917 | 2/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16133626 | 0.84 | CACNA1B (0.43) | SMOFLT3HASPINL3MBTL1CACNA1B | |
| SCHEMBL19323027 | 0.76 | SMN1; SMN2 (0.38) | MEN1KMT2AFLT3HASPIN | |
| SCHEMBL16136259 | 0.76 | KDM4E (0.45) | KMT2AFLT3HASPINL3MBTL1ELANE | |
| SCHEMBL16768672 | 0.72 | FLT3 (0.31) | FLT3HASPIN | |
| SCHEMBL17447472 | 0.71 | SMO (0.46) | SMOMEN1KMT2ATDP1RIPK1 | |
| SCHEMBL20417155 | 0.70 | QPCT (0.46) | — | |
| SCHEMBL19176853 | 0.69 | SMO (0.40) | SMOMEN1KMT2ATDP1RIPK1 | |
| SCHEMBL20625833 | 0.69 | CCR2 (0.39) | MEN1KMT2ARIPK1CNR1CCR2 | |
| SCHEMBL24827544 | 0.68 | KDM4E (0.41) | TDP1L3MBTL1 | |
| SCHEMBL17447491 | 0.68 | RAB9A (0.55) | SMOMEN1KMT2ATDP1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180208591-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208591-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | CYP3A5, PAICS, CYP4B1 | SMO 1462/4885MEN1 1273/4885KMT2A 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.